Progressive multifocal leukoencephalopathy (PML) is a rare subacute demyelinating disorder of the central nervous system (CNS) caused by the DNA JC human polyomavirus. In immunocompromised hosts, PML is caused by reactivation of a latent infection rather than de novo primary exposure. PML in the setting of hematopoietic cell transplantation (HCT) is exceedingly rare. PML should be considered in the differential diagnosis of HCT recipients, autologous or allogeneic, presenting with worsening of neurological symptoms, especially associated with post-transplant neurodegenerative findings. Although DNA polymerase chain reaction (PCR) of the cerebrospinal fluid (CSF) has emerged as a promising tool for detecting JC virus, a negative result does not rule out PML. Brain biopsy remains the most reliable and accurate method for diagnosing JC virus-associated PML. Presently, there is no universally effective antiviral therapy against JC virus and outcome is fatal in the majority of cases. We hereby describe two cases of PML developing after allogeneic HCT and provide a comprehensive review of the literature.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a rare subacute-demyelinating disorder of the central nervous system (CNS) caused by the DNA JC human polyomavirus. 1 It occurs in immunocompromised individuals and was first described in 1958 in patients with Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL). 2 A recent increase in PML prevalence has been observed in association with HIV infection, in patients with the acquired immune deficiency syndrome (AIDS). 3 Clinicopathological studies suggest a prevalence of PML approximately 5% in HIV-infected patients. 4 Presently 85% of cases of PML are diagnosed in the setting of AIDS. 5 In patients with AIDS, JC virus-specific CD4 T-cell responses play a crucial role in controlling JC virus infection and preventing development of PML. 6 Most of our current understanding of PML resulted from studies and clinical observations in HIV/AIDS patients.
There have been several cases of PML associated with fludarabine therapy, mainly in patients with CLL. [7] [8] [9] [10] Also, a detailed review of cases of PML in patients with multiple sclerosis exposed to natalizumab, an a 4 integrin antagonist in a class of selective adhesion-molecule inhibitors, suggested a risk of PML of approximately 1 in 1000 treated patients for a mean of 17.9 months.
11 PML has been also described in patients receiving pharmacologic immunosuppression for solid-organ transplantation. 12 PML in the setting of hematopoietic cell transplantation (HCT) is exceedingly rare. We hereby describe two cases of PML following allogeneic HCT and provide a review of the literature.
Descriptive cases Case 1. A 51-year-old man with diagnoses of relapsedfollicular non-Hodgkin's lymphoma and secondary myelodysplasia (cytogenetic: 20qÀ) underwent an allogeneic, mismatched (A-antigen, B-allele), ABO incompatible, unrelated HCT with cyclophosphamide and total body irradiation (12 Gy) conditioning. His pre-transplant serology was negative for cytomegalovirus (CMV), hepatitis B, hepatitis C, HIV and HTLV. His donor was CMV seropositive. Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate and tacrolimus. Hematologic engraftment was documented on day þ 18. His post-transplant course was complicated by biopsy-proven acute GVHD involving the skin and gastrointestinal tract requiring systemic therapy with prednisone and mycophenolate mofetil, Aspergillus pneumonia requiring treatment with caspofungin and voriconazole, and BK virus-related hemorrhagic cystitis. Chimerism studies from the peripheral blood around day þ 75 demonstrated a 100% donor by CD3 and 99% by CD33. On day þ 125, a bone-marrow aspirate and biopsy documented evidence of cytogenetic, hematologic and molecular remission. A PET scan, however, demonstrated very mild radiopharmaceutic uptake in the periaortic, inguinal, iliac and presacral areas. On day þ 165, he developed confusion and disorientation, dysnomia and progressive right upper extremity weakness. He also developed one episode of grand-mal seizure. An extensive work up including a magnetic resonance imaging (MRI) of the brain showed abnormal increased fluidattenuated inversion recovery (FLAIR) signal in the periventricular and subcortical white matter (Figure 1a) . Also, gyriform areas of abnormal increased FLAIR signal were seen in the left frontal and parietal lobes. In addition, multiple smaller foci of increased T2 and FLAIR signal were seen throughout the periventricular white matter clustered within the left centrum semiovale. A complete blood count disclosed evidence of profound lymphopenia (absolute lymphocyte count ¼ 230/ml). Cerebrospinal fluid (CSF) analysis showed elevated proteins at 123 mg/dl (normal range: 12-60 mg/dl), but normal glucose levels. Case 2. A 41-year old Caucasian male presented with relapsed Hodgkin's lymphoma after high-dose chemotherapy (HDCT) and autologous HCT. Following conventional salvage chemotherapy with ifosfamide, etoposide and carboplatinum for two cycles, he received myeloablative doses of intravenous busulfan targeted to an average concentration at steady state of 800-1000 ng/ml and fludarabine at 40 mg/m 2 intravenously for 4 days, followed by allogeneic peripheral blood stem cell transplantation from a matched-sibling donor. Recipient serologies were positive for EBV, CMV, HSV and varicella zoster virus (VZV). Donor serologies were positive for EBV, CMV and VZV. GVHD prophylaxis consisted of methotrexate and tacrolimus. The post-transplantation course was complicated with biopsy-proven GVHD grade III, affecting the gastrointestinal tract only. He responded transiently to systemic glucocorticoids in the short term, but required addition of mycophenolate mofetil to maintain GVHD remission. On day þ 196, he presented to another institution after 10 days of progressive slurred speech and right upper extremity weakness. Initial work up with gadolinium-enhanced MRI and CSF analysis was unrevealing, and he was transferred to our center for further management. A follow-up MRI showed nonspecific increased FLAIR and diffusion signal in the precentral gyri bilaterally. A complete blood count disclosed lymphopenia (absolute lymphocyte count ¼ 880/ml). CSF analysis showed normal glucose and protein concentration, as well as cell counts and cytology. Routine cultures for bacteria, AFB, fungi and virus were negative. PCR for EBV, HSV, CMV and HHV 6 were negative. IgM was negative for Arbovirus. Anti-HU antibody was negative. His neurological status rapidly deteriorated over a period of 3 weeks with the development of asymmetric spastic quadriparesis and bulbar paralysis. A repeat MRI 3 weeks later showed increased signal within the white matter of the corona radiata bilaterally and also involvement of the cortical surface and subcortical white matter in the left occipital region. CSF DNA for JC virus was positive by PCR. Tacrolimus immunosuppression was withdrawn without clinical evidence of improvement. At the request of family, the patient was discharged to a hospice and died on day þ 225 post transplantation. The interval between onset of clinical manifestations of PML and death was 29 days.
Discussion
The recent increase in incidence of PML seen in association with the AIDS epidemic has motivated researchers to better understand the pathobiologic, diagnostic and therapeutic aspects of the disease. Most of our current understanding of PML originated from studies and clinical observations in the HIV/AIDS population. However, it remains unclear why PML is more common in HIV/AIDS than other underlying immunosuppressive settings including postallograft HCTs. Possible postulated mechanisms include a direct effect of HIV virus on the CNS that facilitates entry of the JC virus into the brain. 4 It is very likely that other mechanisms are also involved in the development of PML in HIV/AIDS patients. We performed a MEDLINE search for articles describing PML in the setting of HCT for the time period covering 1966 to May 2006. Articles other than English were analyzed and reviewed if an abstract in English was available. Our search identified four cases of PML developing after allogeneic HCT (Table 1 ) and eight after HDCT and autograft (Table 2) .
In patients developing PML following allografts, 13-16 the median age of recipients was 37.5 years (range: 29-44). Time from allograft infusion to onset of PML range from 1.5 to 17 months. Outcome was fatal in three of four cases. One patient was alive after interleukin-2 (IL-2) therapy with improvement in neurologic symptoms within 5 days of initiating therapy, and resolution of symptoms afterwards.
14 Interestingly, that patient had low CD4 count of 57/mm 3 that increased to 279/mm 3 after 6 weeks of IL-2 therapy. These findings suggest that IL-2 may have contributed to increasing CD4 counts and resolution of symptoms. However, the diagnosis of PML in that case was based on radiologic and clinical findings rather than tissue diagnosis, DNA analysis or electron microscopy, raising concern whether it could be indubitably attributed to JC virus.
There are eight reported cases of PML after autologous HCT [17] [18] [19] [20] [21] [22] [23] (Table 2 ). The median age of autograft recipients was 44 years (range: 31-60). The time to PML onset ranged from 1 to 20 months. Clinical presentation consisted of a combination of motor, sensory and cognitive dysfunctions. Outcome was fatal in four cases with time from PML onset to death ranging from 2 to 7 months. Two patients were alive, at 11 and 12 months from diagnosis, after intrathecal cytarabine plus IL-2 SQ in one case, 20 or IL-2 by low-dose continuous intravenous (i.v.) infusion in another. 21 Resolution of symptoms correlated with recovery of CD4 counts after IL-2, 21 suggesting an important role for immune reconstitution in PML. One patient was alive despite no therapy. 17 Two patients died despite receiving IL-2 (in combination with interferon, AS101 and intrathecal cytarabine) in one, 19 and intravenous IL-2 plus cidofovir in another. 17 Interestingly, the lack of universal responses to IL-2 raises question whether resolution of symptoms resulted from a more rapid reconstitution of the immune system particularly in the setting of autologous HCT, rather than a direct effect of IL-2 per se. Cidofovir was administered as monotherapy to a patient with a CD4 count of 535/mm 3 without clinical benefit. 18 Neurological complications are not considered among the most important causes of morbidity and mortality following HCT. Nonetheless, Gallardo et al.
24 demonstrated a 37% incidence of neurologic symptoms in allograft recipients. Cerebrovascular events and infections were the most severe complications accounting for 26% of causes of death. 24 Similarly, Mohrmann et al. 25 examined neuropathologic tissues following necropsy of 109 patients who underwent bone marrow transplantation. The most common findings included: cerebrovascular (26.6%), bacterial and fungal infections (12.8%), and leukoencephalopathy (7.3%). 25 A syndrome of posterior reversible encephalopathy (PRES) has been described in recipients of allogeneic HCT in association with calcineurin inhibitors (CI), namely cyclosporine and tacrolimus. 26, 27 The clinical presentation of PRES is nonspecific and may include mental status changes, cognitive deficits, seizures and lethargy. In most cases, symptoms resolve after discontinuation of the CI. In one series, the overall incidence of PRES following treatment with tacrolimus is approximately 1.6%. 27 Exposure to JC polyoma virus occurs during the first decades of life 1, 28 and is asymptomatic in immunecompetent hosts. The precise route of transmission is unclear, but respiratory and gastrointestinal routes are favored. Also, there is evidence supporting perinatal transmission. The seroprevalence rate in adults is 70-90%. 29 In immunocompromised hosts, JC virus associated-PML is caused by reactivation of a latent infection rather than de novo exposure. The majority of cases lack anti-JC IgM antibodies (Abs) in the presence of pre-existing anti-JC IgG Abs that do not increase further during the course of disease. Although DNA PCR of the CSF has emerged as a promising tool for detecting JC virus, brain biopsy remains the most reliable and accurate method for diagnosing PML. 1 Fong et al. 33 showed that sensitivity and specificity of JC virus DNA by PCR are 74% and 95.8%, respectively, whereas the positive and negative predictive values are 89.5% and 88.5%, respectively. There remain many factors that would preclude a definitive diagnosis based on CSF only, hence a negative result must be considered in the context of the complete clinical picture. Although histopathologic changes may limit the pathologic diagnosis to 'inflammatory demyelination', the changes in other cases are fairly distinctive, particularly with identification of intranuclear inclusions in enlarged oligodendroglia. Final confirmation may be sought by electron microscopy where viral particles are apparent as spherical and filamentous forms within oligodendroglia. In patients with HIV/AIDS, absence of JCV DNA in blood has been shown to be associated with a low probability of developing PML. 34 The significance of JC viremia, or absence of it and its potential as a PML screening tool in recipients of HCT remains to be assessed.
In patients with AIDS, JC virus-specific CD4 T-cell responses play a crucial role in controlling JC-virus infection and preventing development of PML; 6 such responses can be restored in PML survivors with effective anti-retroviral therapy, suggesting an important role for immunomodulation in the management of PML. 6 In post-HCT, there are anecdotal cases showing that recovery of CD4 lymphocyte counts correlate with resolution of PML symptoms. 14, 21 There is no universally effective anti-viral therapy against PML developing after autologous or allogeneic HCT and outcome is fatal in most cases. Treatment options include IL-2 (i.v. or subcutaneous), cytarabine (i.v. or intrathecally), cidofovir i.v., alone or in combination, and withdrawal of immunosuppression medications. Pho et al. 35 showed that the neuroleptic drug, chlorpromazine, inhibits the endocytic pathway used by JC virus to infect glial cells. Atwood. 36 described that nontoxic doses of chlorpromazine effectively inhibit JC virus multiplication and spread in a tissue culture model. Altschuler et al. 37 reported that new-generation atypical antipsychotics such as ziprasidone, risperidone and olanzapine are significantly more potent, in vitro, 5HT2A receptor antagonists than chlorpromazine or clozapine and may be useful therapies for PML.
In our first case, we rationalized the use of ziprasidone based on the published literature. 30, [35] [36] [37] However, we did not appreciate any evidence of clinical improvement despite ziprasidone-inducing significant sedative side effects. These findings raise the question whether higher doses, than clinically tolerated, are required to achieve a beneficial effect. Consistent with findings reported by others, 13 cidofovir did not appear to retard the aggressive clinical course of PML in our case. IL-2 was not used, in the first case, owing to the presence of active GVHD. Reddy et al. 38 showed that IL-2 enhances T-cell expansion, induces maturation of cytotoxic T-cells (CTL) and natural killer (NK) cells potentially augmenting a GVHD response.
In our second case, the predominant involvement of the gray matter on initial MRI is atypical for PML. Nevertheless, gray-matter involvement with PML have been previously reported. 39, 40 Sarrazin et al. 39 reported a case of biopsy-proven PML with thalamic involvement. Mark et al. 40 demonstrated that PML involvement where lesions were distributed throughout the brain, including the brain stem and basal ganglia in 10 patients with AIDS. In their series, white matter was affected in all 10 patients, whereas gray matter was involved in five. Also, consistent with the literature, both cases described herein (case nos. 1 and 2) had lymphopenia at time of neurologic symptomatology suggesting a key role for immune deficiency in the pathogenesis of PML. Our patient (case no. 2) did not respond to withdrawal of immunosuppression, that was intended to expedite immune reconstitution, and his rapidly worsening clinical and neurologic condition resulting from progression of PML did not allow for administration of additional therapies.
Conclusion
PML in the setting of autologous or allogeneic HCT is rare and there is no universally effective therapy. Treating physicians should have a high index of suspicion for PML, especially in profoundly immunosuppressed transplant recipients. It is also important to keep in mind that a negative CSF-PCR analysis for the JC virus does not rule out PML; and in those cases a brain biopsy is recommended for definitive diagnosis. Physicians should also evaluate patients for other infectious etiologies of encephalitis including viral (HSV, HHV 6 , CMV, West Nile virus and others), bacterial or fungal. PML is a fatal disease that should be considered in the differential diagnosis of HCT recipients presenting with worsening of neurological symptoms, especially those associated with post-transplant neurodegenerative findings.
